Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8686292 | 0.79 | GABRA1 (0.40) | RXFP1CCR1CCR5CCR8NOS3 | |
| SCHEMBL18791377 | 0.78 | DAO (0.34) | RXFP1MPIMAPTKMT2ALMNA | |
| SCHEMBL12528205 | 0.75 | NOS2 (0.54) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL12051932 | 0.75 | MAPT (0.36) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL18811974 | 0.75 | SMN1; SMN2 (0.35) | MAPTKMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL21567478 | 0.75 | CCR1 (0.35) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL13911701 | 0.75 | NR4A2 (0.36) | MAPTLMNASMN1; SMN2 | |
| SCHEMBL2696817 | 0.75 | GABRA1 (0.39) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL10329935 | 0.72 | CCNA2 (0.38) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL13827094 | 0.71 | MAPT (0.35) | MAPTKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110311516-A1 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-7365211-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | RXFP1 4707/4885CCR1 4653/4885CCR5 4601/4885 |
| US-20110311516-A1 | Chemically Programmed Vaccination | CD69, CD4, ICOS | RXFP1 4213/4885CCR1 126/4885CCR5 180/4885 |
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | RXFP1 1380/4885CCR1 610/4885CCR5 1178/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | RXFP1 1380/4885CCR1 610/4885CCR5 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.